Minerva Neurosciences Inc (NAS:NERV)
$ 2.48 -0.04 (-1.59%) Market Cap: 17.34 Mil Enterprise Value: -17.20 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 37/100

Minerva Neurosciences, Inc. - Special Call Transcript

Jun 05, 2020 / 12:30PM GMT
Release Date Price: $31.36 (-7.98%)
Operator

Greetings, and welcome to the management call to discuss results from Phase III trial of roluperidone hosted by Minerva Neurosciences. (Operator Instructions) As a reminder, this conference is being recorded. I would now like to turn the call over to your host. Mr. Bill Boni, Director of Investor Relations at Minerva Neurosciences.

William B. Boni
Minerva Neurosciences, Inc. - VP of IR & Corporate Communications

Good morning, and welcome. This is Bill Boni, VP of Investor Relations at Minerva. Welcome to the company's June 5, 2020 conference call to discuss additional analysis from the Phase III trial of roluperidone to treat negative symptoms in schizophrenia. Top line results from this trial were announced on May 29, 2020.

The Minerva management team, led by Dr. Remy Luthringer, Executive Chairman and Chief Executive Officer; is joined today by key opinion leaders, Dr. Phil Harvey; and Dr. Brian Kirkpatrick. Dr. Harvey is Leonard M. Miller Professor of Psychiatry and Director of the Division of Psychology at the University of Miami, Miller

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot